Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002313609 | SCV000848741 | uncertain significance | Inborn genetic diseases | 2021-07-16 | criteria provided, single submitter | clinical testing | The c.505C>A (p.L169I) alteration is located in exon 5 (coding exon 4) of the VPS13B gene. This alteration results from a C to A substitution at nucleotide position 505, causing the leucine (L) at amino acid position 169 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV001247920 | SCV001421373 | likely benign | Cohen syndrome | 2024-01-22 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003403651 | SCV004104277 | uncertain significance | VPS13B-related disorder | 2023-11-30 | criteria provided, single submitter | clinical testing | The VPS13B c.505C>A variant is predicted to result in the amino acid substitution p.Leu169Ile. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.13% of alleles in individuals of African descent in gnomAD. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Natera, |
RCV001247920 | SCV002079434 | uncertain significance | Cohen syndrome | 2019-11-11 | no assertion criteria provided | clinical testing |